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Abstract
Background: Fumarate hydratase (FH) deficiency is a rare autosomal recessive disorder which results in a major
defect in cellular metabolism. It presents in infancy with progressive encephalopathy, hypotonia, seizures and failure
to thrive and is often fatal in childhood. It is caused by mutations in the FH gene (1q42.1) that result in deficiency
of the citric acid cycle enzyme fumarate hydratase, resulting in accumulation of fumaric acid. Heterozygous
germline mutations in the FH gene predispose to an aggressive autosomal dominant inherited early-onset kidney
cancer syndrome: hereditary leiomyomatosis and renal cell cancer (HLRCC).
Case presentation: Cascade FH mutation screening enabled the early diagnosis of a renal tumour in an
asymptomatic parent of a child with fumarate hydratase deficiency, resulting in timely and possibly life-saving
treatment.
Conclusion: While the theoretical risk of kidney cancer in parents of children with recessive fumarate hydratase
deficiency is well recognized, to our knowledge this is the first report of a kidney tumour being detected in a
parent by screening performed for this indication. This underscores the importance of offering lifelong kidney
surveillance to such parents and other heterozygous relatives of children born with fumarate hydratase deficiency.
Keywords: Fumarate hydratase deficiency, Hereditary leiomyomatosis and renal cell cancer (HLRCC), Hereditary
cancer, Case report
Background
Inherited cancer syndromes are an important cause of
disease, accounting for 5-10% of cancers in the general
population [1]. These disorders are usually inherited as
dominant traits and therefore afflict multiple generations
of the same family, either in childhood or adulthood.
Early diagnosis can have major survival benefits and ac-
tive surveillance for cancer from a young age allows tu-
mors to be safely removed before they have
metastasized. A detailed family history is therefore a cru-
cial part of the assessment of all patients with cancer.
Identification of the mutated genes responsible for
inherited cancer syndromes is important because bi-
allelic somatic mutations in the same genes are fre-
quently found in sporadic cancers; a major cause of
death in the general population. Defining these genes
has provided some key insights into the cellular mecha-
nisms responsible for cancer.
Kidney cancer kills approximately 4250 people each
year in the UK (~3% cancer deaths) [2]. It frequently
presents late, often only detected incidentally during
radiological imaging of the abdomen, and if it has metas-
tasized at time of diagnosis, may prove fatal. Early detec-
tion of renal lesions in at-risk individuals can therefore
be life-saving.
Here, we present a case of a kidney tumour associated
with hereditary leiomyomatosis and renal cell cancer
(HLRCC) that was diagnosed by cascade screening of
the healthy parents of an infant with autosomal recessive
fumarate hydratase deficiency.
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Case presentation
The index case is the first child of unrelated healthy
Caucasian parents. Antenatal ultrasound identified the
child had dilated cerebral ventricles and she was induced
at term for this reason. She had an uncomplicated deliv-
ery and was of normal birth weight. There was initial
concern about jaundice but no specific treatment was
required.
She presented at 3 months of age with seizures and
hypotonia although her parents had noted some visual
inattentiveness and developmental delay prior to presen-
tation. Seizure control was challenging with short pe-
riods of good control being achieved with multiple
anticonvulsant agents. On examination, she was plagio-
cephalic, with an alternating divergent strabismus, a
wide mouth with tented upper lip and some facial coars-
ening. An MRI scan showed a delay in myelination and
evidence of poor white matter bulk.
Urinary organic acid analysis by gas-chromatography
mass spectrometry showed raised fumarate (4790 μmol/
mmol creatinine) with mildly raised succinate and 2-
oxoglutarate levels. Functional enzyme analysis in fibro-
blasts showed fumarate hydratase activity of 20% control
level, and genetic analysis of the FH gene showed com-
pound heterozygosity for mutations in c.844G>C
p.Gly282Arg (present in the father) and c.1127A>C
p.Gln376Pro (inherited from the mother), confirming a
diagnosis of fumarate hydratase deficiency.
Developmental progress was very slow. She was bab-
bling and rolling at 2 years of age but did not achieve in-
dependent sitting and her development plateaued from
around 2.5 years. She had significant central visual im-
pairment limited to perception of light. There were epi-
sodes of status epilepticus and latterly episodes of
abnormal posturing and dystonia. Her growth faltered
and she failed to thrive, her weight fell below the 0.4th
centile and she died at 4 years of age.
The parents were offered screening by renal ultrason-
ography in view of their known heterozygous mutations
in the FH gene. An ultrasound of the 30-year-old asymp-
tomatic father showed a cystic lesion at the lower pole
of the left kidney. MRI scan confirmed a
2 cm × 2 cm × 1.8 cm cystic exophytic lesion (Fig. 1).
There was no evidence of metastatic spread and he
underwent a robot-assisted laparoscopic partial left
nephrectomy from which he made an uneventful recov-
ery. Histological examination of the renal lesion demon-
strated a low grade tubulocystic carcinoma, with cysts
lined by hob-nailing cells containing eosinophilic cyto-
plasm and rounded nuclei with conspicuous nucleoli,
which had been completely resected (Fig. 2). Immuno-
histochemistry showed positivity for CD10, vimentin and
CK19 and was negative for CK7, racemase, and RCC.
FH and 2-Succinocysteine (2SC) immunohistochemistry
was not assessed in line with current routine clinical
practice.
Discussion and conclusions
Approximately 3-5% of all kidney cancers are inherited
and at present there are ten syndromes and 12 genes
that have been found to be associated with an increased
risk of kidney cancer [3]. Heterozygous mutations in
genes including VHL, Fumarate hydratase (FH) and Suc-
cinate dehydrogenase subunits (SDHB, SDHC and
SDHD) are associated with different types of renal can-
cers and somatic loss of the second allele can often be
demonstrated in the associated renal lesions. Many of
the genetic defects associated with inherited kidney can-
cer syndromes perturb cellular metabolism by disrupting
the citric acid cycle and the renal lesions associated with
these different molecular defects have different histo-
logical and clinical characteristics. Here we present a
case of an FH-associated kidney tumour identified by
screening an asymptomatic parent of a child with auto-
somal recessive fumarate hydratase deficiency caused by
compound heterozygous mutations in the FH gene.
Heterozygous loss-of-function FH mutation is associ-
ated with hereditary leiomyomatosis and renal cell can-
cer (HLRCC) syndrome [4]. The clinical manifestations
include uterine fibroids (present in 75-98% of female
mutation carriers) often requiring myomectomy or hys-
terectomy before the age of 40 years [4–6]; painful cuta-
neous leiomyomata (present in 76-100% of mutation
carriers, with mean age of onset of 25 years) [5, 7, 8];
and renal cell carcinomas (RCCs) which occur with vari-
able penetrance in approximately 14-18% of affected in-
dividuals [7, 9]. Following the recognized association
with renal cancer, the term HLRCC has superseded the
earlier terms Reed’s Disease [10] and Multiple Cutane-
ous and Uterine Leiomyomata syndrome (MCUL) [4].
Fig. 1 Abdominal MRI showing a 2 × 2 × 1.8 cm exophytic lesion
in the lower pole of the left kidney demonstrating septation
and enhancement
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HLRCC-associated RCCs are a group of histologically
heterogeneous tumors that can be described as papillary,
solid, tubulocystic, cribiform or cystic in nature and have
recently been added as a separate entity to the 2016
WHO Classification [11]. Cells share a characteristic
appearance; a large nucleus and prominent inclusion-like
eosinophilic nucleoli surrounded by a clear halo [12]. Im-
munohistochemistry demonstrates a lack of FH protein
expression and increased 2SC levels in the tumor [13–15];
a finding that should prompt genetic screening of affected
individuals. Traditionally ‘type 2 papillary RCCs’ were the
renal lesion most commonly associated with HLRCC,
however a recent genomic analysis has suggested that
‘type 2 papillary RCC’ is not in fact a single tumor type,
but instead consists of sub-groups with different molecu-
lar backgrounds [16]. Interestingly, DNA methylation ana-
lysis identified a CpG island methylator phenotype
(CIMP) which was associated with reduced FH mRNA ex-
pression; this was seen in 56% of tumors with germline
FH mutations and associated with poor survival [16].
It is clinically important to differentiate FH-deficient
RCC from other renal cell cancers as the former have a
high chance of early invasion and metastasis, even when
the lesion diameter is very small (<1 cm). This contrasts
with most sporadic renal cell carcinomas and those as-
sociated with other inherited conditions (such as VHL
disease), in which tumours smaller than 3 cm in diam-
eter tend to be well circumscribed with a very low
probability of metastasis. This distinction suggests that
aggressive screening (by regular high-resolution im-
aging) and early resection of even very small suspi-
cious lesions that are identified in patients with
HLRCC may be necessary to reduce the risk of fatal
metastatic cancer [17]. Management of these lesions
requires early nephron-sparing surgery and a Phase II
clinical trial (NCI 10-C-0114) for the treatment of ad-
vanced or metastatic HLRCC-associated kidney cancer
using bevacizumab (targeting VEGFA) and erlotinib
(targeting EGFR kinase activity) is currently under way
(NCT01130519).
a
b c
Fig. 2 Histology shows a multicystic tumour with cysts lined by hobnailed cells (arrow) with a low mitotic index and prominent nucleoli (a, low power;
b, high power). Within the stroma are tubular elements with similar nuclear features (c)
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Germline mutations in the FH gene are diagnostic for
HLRCC and approximately 120 potentially pathogenic
mutations have been identified [18]. Genetic testing
should be offered to anyone with clinical manifestations
of the syndrome or with a family history of HLRCC. The
renal tumours seen with HLRCC can present at a young
age (10-44 years) and current recommendations suggest
considering screening children with a known heterozy-
gous FH mutation with abdominal MRI annually from
the age of 8 years [19].
The FH gene has been suggested as a ‘non-classical’
tumour suppressor gene. It encodes the enzyme fumarate
hydratase which catalyses the conversion of fumarate to
malate in the citric acid cycle. Deficiency of this enzyme
results in excessive fumarate accumulation and it is
hypothesised that fumarate may act as an ‘oncometabolite’
in FH-deficient kidney cancer [17]. One theory is that the
excess fumarate induces an environment of ‘pseudo-
hypoxia’ by stabilisation of the transcription factor
hypoxia-inducible factor 1-alpha (HIF-1α) and upregu-
lation of its target genes vascular endothelial growth
factor (VEGF) and glucose transporter 1 (GLUT1) creat-
ing optimal conditions for tumour proliferation. Alterna-
tively, it has been proposed that fumarate may indirectly
stabilise the transcription factor nuclear factor erythroid
2-related factor 2 (Nrf2) and result in activation of the
Nrf2 antioxidant pathway [20].
While HLRCC is caused by heterozygous FH mutations,
and transmitted as an autosomal dominant trait, inherit-
ance of two defective FH alleles has been described in
around 100 patients, and is associated with a significant
deficiency of the fumarate hydratase enzyme. This causes
a major defect of cellular metabolism which usually
manifests in the peri-natal period or in early infancy.
Dysmorphology is frequently present and characteristic
features include a depressed nasal bridge, widely spaced
eyes, frontal bossing, ear anomalies and narrow forehead.
Brain atrophy and white matter abnormalities are also
described [21]. Clinical features include encephalopathy,
poor feeding, lethargy, stupor and epilepsy. Other reports
include recurrent vomiting and hepatosplenomegaly [21],
neonatal polycythaemia [22] and pancreatitis [23]. Clinical
outcomes in these infants are unfortunately poor with
progressive neurological and systemic disease leading to
death in infancy or early childhood in most cases [24].
While the theoretical risk of kidney cancer in parents
of children with recessive fumarate hydratase defi-
ciency is well recognized, to our knowledge this is the
first report of identification of a parent with a kidney
tumour by screening performed for this indication.
This underscores the importance of offering lifelong
kidney surveillance to such parents and other hetero-
zygous relatives of children born with fumarate hydra-
tase deficiency.
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